Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J COLEBATCH

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Pathology|January 3, 2021
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretationElizabeth C Paver, Wendy A Cooper, Andrew J Colebatch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2025
Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic TumorsIsmael A Vergara, Nigel G Maher, Alison J Potter, et al.
The American Journal of Surgical Pathology|April 19, 2022
Comprehensive Clinical, Histopathologic, and Molecular Analysis and Long-term Follow-up of Patients With Nodal Blue NeviAndrew J Colebatch, Chandra Adhikari, Russell J Diefenbach, et al.
The Australasian Journal of Dermatology|February 21, 2022
Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanomaThomas E Pennington, Cathy Yunjia Zhao, Andrew J Colebatch, et al.
Oncotarget|November 19, 2016
Novel metastatic models of esophageal adenocarcinoma derived from FLO-1 cells highlight the importance of E-cadherin in cancer metastasisDavid S Liu, Sanne J M Hoefnagel, Oliver M Fisher, et al.
Pathology|March 7, 2022
Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centreAlison J Potter, Andrew J Colebatch, Robert V Rawson, et al.
Nature Cancer|December 11, 2020
Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrenceWiebke Pruessmann, Julie Rytlewski, James Wilmott, et al.
Genome Medicine|May 26, 2026
Enhanced measures of neoantigenicity capture unique tumor-immune interactions across primary melanoma subtypesEva R Shteinman, Grace H Attrill, Nigel G Maher, et al.
Scientific Reports|July 26, 2018
Multiplex immunohistochemistry accurately defines the immune context of metastatic melanomaH Halse, A J Colebatch, P Petrone, et al.
Nature Cancer|February 5, 2022
Publisher Correction: Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrenceWiebke Pruessmann, Julie Rytlewski, James Wilmott, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Pathology|January 3, 2021
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretationElizabeth C Paver, Wendy A Cooper, Andrew J Colebatch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2025
Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic TumorsIsmael A Vergara, Nigel G Maher, Alison J Potter, et al.
The American Journal of Surgical Pathology|April 19, 2022
Comprehensive Clinical, Histopathologic, and Molecular Analysis and Long-term Follow-up of Patients With Nodal Blue NeviAndrew J Colebatch, Chandra Adhikari, Russell J Diefenbach, et al.
The Australasian Journal of Dermatology|February 21, 2022
Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanomaThomas E Pennington, Cathy Yunjia Zhao, Andrew J Colebatch, et al.
Oncotarget|November 19, 2016
Novel metastatic models of esophageal adenocarcinoma derived from FLO-1 cells highlight the importance of E-cadherin in cancer metastasisDavid S Liu, Sanne J M Hoefnagel, Oliver M Fisher, et al.
Pathology|March 7, 2022
Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centreAlison J Potter, Andrew J Colebatch, Robert V Rawson, et al.
Nature Cancer|December 11, 2020
Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrenceWiebke Pruessmann, Julie Rytlewski, James Wilmott, et al.
Genome Medicine|May 26, 2026
Enhanced measures of neoantigenicity capture unique tumor-immune interactions across primary melanoma subtypesEva R Shteinman, Grace H Attrill, Nigel G Maher, et al.
Scientific Reports|July 26, 2018
Multiplex immunohistochemistry accurately defines the immune context of metastatic melanomaH Halse, A J Colebatch, P Petrone, et al.
Nature Cancer|February 5, 2022
Publisher Correction: Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrenceWiebke Pruessmann, Julie Rytlewski, James Wilmott, et al.
Pageof 9